需要ECMO支持患者的死亡风险预测模型
该系统评价检索4905篇文献,纳入96项研究、58个模型和225次外部验证,评估成人V-A或V-V ECMO全因死亡多变量预测模型的性能。为ECMO患者开发的58个模型中仅14个(24%)曾被外部验证;常用模型SAVE与RESP评分的汇总c统计量为0.66–0.70,与SAPS II、APACHE II、SOFA等通用ICU模型(汇总c统计量0.66–0.69)相当。几乎所有模型倾向低估死亡(汇总O:E>1),外部验证性能报道变异大、研究间异质性大,58个模型中仅1个符合PROBAST良好质量标准。所有预测结局均以ECMO已启动为前提,限制了其在临床实践中用于患者选择的适用性。
要点
- 为ECMO患者开发的58个死亡预测模型中仅14个(24%)曾被外部验证,绝大多数缺乏外部验证。
- 常用ECMO模型SAVE与RESP评分的汇总c统计量为0.66–0.70,判别能力中等,与通用ICU模型SAPS II、APACHE II、SOFA(汇总c统计量0.66–0.69)相当。
- 几乎所有模型倾向低估死亡,汇总O:E>1,即预测死亡风险低于实际观察到的死亡。
- 外部验证报告的性能指标变异大,反映研究间人群与模型性能存在较大异质性。
- 所有模型均在已启动ECMO的患者中开发,不能用于决定谁应启动ECMO的患者选择决策支持。
适用人群与场景
- 需要或正在接受V-A或V-V ECMO支持的成人难治性心循环或呼吸衰竭患者。
- 所有预测结局均以ECMO支持已启动为前提,不适用于ECMO启动前的患者选择。
研究设计与关键结果
- 系统评价共筛选4905篇文章,纳入96项研究,描述58个模型和225次外部验证。
- 58个专为ECMO患者开发的模型中,14个(24%)曾被外部验证。
- SAVE和RESP评分等常被验证的ECMO模型汇总c统计量为0.66–0.70,判别能力中等。
- 通用ICU人群模型SAPS II、APACHE II、SOFA评分的汇总c统计量分别为0.66–0.69,与ECMO模型相当。
- 几乎所有模型倾向低估死亡,汇总O:E>1。
- 外部验证报告的性能指标变异大,反映研究间异质性大。
- 58个模型中仅1个符合PROBAST公认的良好质量标准。
- 所有预测结局均以ECMO支持已启动为前提,降低了其在临床实践中用于患者选择的适用性。
证据类型、等级与局限
- 证据类型:系统评价,评估成人ECMO死亡预测模型的开发与外部验证研究。
- 偏倚风险采用预测模型偏倚风险评估工具(PROBAST)评估,58个模型中仅1个符合PROBAST良好质量标准。
- 局限:外部验证报告的性能指标变异大,反映研究间异质性大;仅少数模型曾被外部验证;所有模型均在已启动ECMO的患者中开发,不能为ECMO启动前的患者选择提供决策支持。
对床旁实践的改变
- 现有ECMO死亡预测模型判别能力中等且普遍低估死亡,不能作为ECMO启动前患者选择的决策支持工具。
- SAVE与RESP评分汇总c统计量0.66–0.70,与SAPS II、APACHE II、SOFA等通用ICU模型(0.66–0.69)相当,未显示更优判别力。
- 多数ECMO模型缺乏外部验证且方法学质量总体差,临床使用前需注意其验证状态与质量。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
PURPOSE: To provide an overview and evaluate the performance of mortality prediction models for patients requiring extracorporeal membrane oxygenation (ECMO) support for refractory cardiocirculatory or respiratory failure.
METHODS: A systematic literature search was undertaken to identify studies developing and/or validating multivariable prediction models for all-cause mortality in adults requiring or receiving veno-arterial (V-A) or veno-venous (V-V) ECMO. Estimates of model performance (observed versus expected (O:E) ratio and c-statistic) were summarized using random effects models and sources of heterogeneity were explored by means of meta-regression. Risk of bias was assessed using the Prediction model Risk Of BiAS Tool (PROBAST).
RESULTS: Among 4905 articles screened, 96 studies described a total of 58 models and 225 external validations. Out of all 58 models which were specifically developed for ECMO patients, 14 (24%) were ever externally validated. Discriminatory ability of frequently validated models developed for ECMO patients (i.e., SAVE and RESP score) was moderate on average (pooled c-statistics between 0.66 and 0.70), and comparable to general intensive care population-based models (pooled c-statistics varying between 0.66 and 0.69 for the Simplified Acute Physiology Score II (SAPS II), Acute Physiology and Chronic Health Evaluation II (APACHE II) score and Sequential Organ Failure Assessment (SOFA) score). Nearly all models tended to underestimate mortality with a pooled O:E > 1. There was a wide variability in reported performance measures of external validations, reflecting a large between-study heterogeneity. Only 1 of the 58 models met the generally accepted Prediction model Risk Of BiAS Tool criteria of good quality. Importantly, all predicted outcomes were conditional on the fact that ECMO support had already been initiated, thereby reducing their applicability for patient selection in clinical practice.
CONCLUSIONS: A large number of mortality prediction models have been developed for ECMO patients, yet only a minority has been externally validated. Furthermore, we observed only moderate predictive performance, large heterogeneity between-study populations and model performance, and poor methodological quality overall. Most importantly, current models are unsuitable to provide decision support for selecting individuals in whom initiation of ECMO would be most beneficial, as all models were developed in ECMO patients only and the decision to start ECMO had, therefore, already been made.
参考来源
- Pladet LCA, Barten JMM, Vernooij LM, et al. Prognostic models for mortality risk in patients requiring ECMO. Intensive Care Med. 2023. PMID: 36600027. doi:10.1007/s00134-022-06947-z
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。